Rhythm Pharmaceuticals
RYTM
111 hedge funds and large institutions have $563M invested in Rhythm Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 9 closing their positions.
1,454% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $272K
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
16% more capital invested
Capital invested by funds: $483M → $563M (+$79.3M)
13% more funds holding
Funds holding: 98 → 111 (+13)
0.68% more ownership
Funds ownership: 96.39% → 97.07% (+0.68%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$19.9M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.35M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$2.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.19M |
| 5 |
Goldman Sachs
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.83M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.79M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$1.61M |
| 5 |
Rafferty Asset Management
New York
|
-$1.11M |
RYTM Hedge Fund Activity: Q1 2022 in Review
111 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2022, worth a combined $563M — up 16% from $483M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RYTM positions and 9 closed out — a net gain of 13 holders — while 32 added to existing stakes and 37 trimmed.
The largest buyer was Federated Hermes, adding an estimated $19.9M. The largest seller was Deerfield Management, cutting an estimated $13.8M.
- 111 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2022, up from 98 in Q4 2021.
- Funds reported $563M of Rhythm Pharmaceuticals stock for Q1 2022, up 16% quarter-over-quarter.
- 22 funds opened new Rhythm Pharmaceuticals positions in Q1 2022 and 9 closed out, a net change of +13 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2022 was Federated Hermes, an estimated $19.9M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2022 was Deerfield Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2022.